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Abstract
Context—Biomarker-driven cancer therapy, also referred to as precision oncology, has received 
increasing attention for its promise of improving patient outcomes by defining subsets of patients 
more likely to respond to various therapies.
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Objective—In this collaborative review article, we examine recent literature regarding 
biomarker-driven therapeutics in urologic oncology, to better define the state of the field, explore 
the current evidence supporting utility of this approach, and gauge potential for the future.
Evidence acquisition—We reviewed relevant literature, with a particular focus on recent 
studies about targeted therapy, predictors of response, and biomarker development.
Evidence synthesis—The recent advances in molecular profiling have led to a rapid expansion 
of potential biomarkers and predictive information for patients with urologic malignancies. Across 
disease states, distinct molecular subtypes of cancers have been identified, with the potential to 
inform choices of management strategy. Biomarkers predicting response to standard therapies 
(such as platinum-based chemotherapy) are emerging. In several malignancies (particularly renal 
cell carcinoma and castration-resistant prostate cancer), targeted therapy against commonly altered 
signaling pathways has emerged as standard of care. Finally, targeted therapy against alterations 
present in rare patients (less than 2%) across diseases has the potential to drastically alter patterns 
of care and choices of therapeutic options.
Conclusions—Precision medicine has the highest potential to impact the care of patients. 
Prospective studies in the setting of clinical trials and standard of care therapy will help define 
reliable predictive biomarkers and new therapeutic targets leading to real improvement in patient 
outcomes.
Patient summary—Precision oncology uses molecular information (DNA and RNA) from the 
individual and the tumor to match the right patient with the right treatment. Tremendous strides 
have been made in defining the molecular underpinnings of urologic malignancies and 
understanding how these predict response to treatment—this represents the future of urologic 
oncology.
Keywords
Precision Medicine; Mutations; Sequencing; Genomics
1. Introduction
The past decade has seen an explosion of therapeutic options in urologic oncology, across 
multiple cancer types. Renal cell carcinoma (RCC) patients now have options of tyrosine 
kinase inhibitors, mechanistic target of rapamycin (mTOR) inhibitors, and immunotherapy 
agents. The prostate cancer field has seen the approval of over half a dozen novel agents in 
the past few years, as well as shifting paradigms regarding the temporal sequencing of 
agents [1,2]. Urothelial carcinoma, in addition to defining subsets of patients with best 
response to standard of care chemotherapeutic options, appears poised for novel agents to 
make meaningful impact as well. Clearly, this is an exciting time to be in urologic oncology, 
as there is more promise and hope for our patients than ever before.
Each novel therapy improves outcomes compared with previous generations of standard 
therapy, but unfortunately, the recent improvements in patient survival can be described as 
incremental rather than transformative. However, defined subsets of patients respond well to 
each therapy, and it is likely that these subsets of responders are not the same for all different 
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therapeutic options. The example of trastuzumab (Herceptin) in breast cancer treatment may 
serve as a model for successful development of precision medicine approaches. Trastuzumab 
was the first rationally designed targeted therapy for solid tumors, based on the discovery 
that some breast cancers have a high degree of amplification of Her2/neu [3], and that these 
cancers are associated with worse prognosis [4]. Development of the drug from bench to 
approval spanned 13 yr—and it has now been responsible for a dramatic change in outcome 
for women for this subtype of breast cancer.
In urologic oncology, now comes the challenge of taking these diverse therapeutic 
opportunities, and finding ways to match the right therapy with the right patient: the 
paradigm of precision medicine. In this review we will explore the history, challenges, and 
opportunities inherent in this process, and explore the future of biomarker-driven 
therapeutics in urologic oncology.
Biomarker-driven therapy can refer to multiple approaches to patient stratification and 
selection of management strategies. First, this can refer to classic targeted therapy, in which 
a specific gene product serves as both the biomarker and the target of therapeutic action—
HER2 overexpression in breast cancer, or BRAF mutations in melanoma, are classic 
examples [5]. Secondly, biomarkers may distinguish patients that are preferentially sensitive 
(or resistant) to standard therapeutic options, even though these specific biomarkers are not 
targets themselves (such as triple negative breast cancer or KRAS mutated colorectal 
cancers). Finally, distinct subclasses of cancers may respond in fundamentally different 
manners to various therapeutic interventions—many such subclasses may be identifiable 
using histologic criteria, but others may only be exposed using specific molecular 
biomarkers. We will review these concepts across urologic oncology in a relatively disease-
specific manner. In addition, we will also discuss issues that apply more universally, across 
multiple malignancies and multiple signaling pathways. These include concepts of utilizing 
biomarker-driven stratification to determine sequencing of different therapeutic options, 
implications of tumor heterogeneity for biomarker-driven therapeutics, and the impact of 
novel approaches such an immunotherapy.
The foundations this field is based upon have undergone major advances with the advent of 
novel technologies for molecular profiling of tumor and patient tissue, including next-
generation sequencing of DNA and RNA, improved understanding and profiling of 
epigenetics, and advanced proteomic analysis. Biomarkers can be defined using DNA 
sequencing (targeted or unbiased exome/genome-wide approaches), transcriptome profiling 
(RNA-sequencing or microarray-based gene expression), and in-situ techniques like 
immunohistochemistry or RNA in-situ hybridization to define protein and expression and 
localization [6,7]. Application of these technologies, including systematic studies as part of 
the International Cancer Genome Consortium and The Cancer Genome Atlas projects, has 
led to a massive expansion of the catalog of known alterations in urologic oncology, the 
starting point for defining biomarkers with real relevance for clinical care.
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2. Evidence acquisition
Medline and Google Scholar searches were conducted to identify original articles, review 
articles, editorials, and presented abstracts addressing biomarker driven therapeutics in 
urologic malignancies. Keywords included “biomarker,” “targeted therapy,” “predictors of 
response,” “therapy resistance,” and “heterogeneity.” We limited our initial search to studies 
and investigations published from January 2005 to January 2016. References cited in 
selected articles and in review articles retrieved in our search were also used to identify 
manuscripts that were not included in the initial search. Links to related articles and cross-
reading of citations in related articles were surveyed. The articles that provided the highest 
level of evidence were then evaluated and selected with the consensus of authors. A total of 
103 articles were reviewed. This collaborative review is the result of an interactive peer-
reviewing process by the panel of coauthors.
3. Evidence synthesis
3.1 Targeted therapies in urologic oncology
3.1.1 Androgen signaling in prostate cancer—The oldest form of targeted therapy in 
urology (and perhaps in all of oncology) came with the recognition that ablation of 
androgens via surgical castration resulted in regression of advanced prostate cancer. 
Although not often thought of as targeted therapy, the dependence of prostate cancer on 
androgen signaling forms the basis of the historical and current approach to advanced 
prostate cancer, with androgen ablation representing the mainstay of treatment for the 
disease. The more recent discovery that castration-resistant prostate cancer (CRPC) largely 
maintains its dependency on androgen signaling further underscores the central importance 
of this signaling axis, and multiple novel therapeutics rely on improved targeting of 
androgen signaling over and beyond that which can be achieved using surgical castration or 
convention androgen-deprivation therapy approaches. These include further reductions of 
androgen production by targeting synthetic enzymes such as CYP17, the target of 
abiraterone acetate (Zytiga), and improved inhibition of the androgen receptor itself 
(enzalutamide/Xtandi, ARN-509/apalutamide) and downstream effects on transcription, 
proliferation, and survival of prostate cancer cells. These approaches have been reviewed 
elsewhere [8,9].
A critical question for these next-generation antiandrogen agents going forward is 
determining the patients that will most benefit from their use. Deregulation of the androgen 
signaling axis is common in prostate cancer [6], and alterations in the AR gene itself become 
highly prevalent in CRPC [10]. These include amplification of the AR gene, point 
mutations, and splice variants. The impact of these alterations on response to antiandrogen 
therapy remains unclear, and this is a major focus of ongoing clinical and preclinical 
investigation.
Mutations and gene amplifications in the AR gene itself have long been known to emerge 
and promote resistance in the setting of conventional androgen ablation [11–13]. However, 
implications of these genomic events for patient response to newer agents like enzalutamide 
and abiraterone are less clear, and data has only recently begun to emerge. Several studies 
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suggest that AR amplification and mutation are more common in patients progressing on 
these therapies compared with responders [14], and there are suggestions that amplification 
of AR can predict response to both enzalutamide and abiraterone [15,16]. Preclinical models 
have shown that constitutively active, truncated androgen receptor splice variants can 
continue to drive androgen signaling in CRPC cells, and that this activity can promote 
resistance to enzalutamide [17]. Clinical studies have also reported that the presence of one 
such androgen receptor splice variant in circulating tumor cells from patients with CRPC is 
correlated with resistance to second-generation androgen targeting agents [18], and may 
emerge during therapy [19]. Across all these questions, larger, rigorously conductive clinical 
studies and correlative genomic analysis will be necessary to provide definitive answers.
3.1.2 Neuroendocrine prostate cancer—A subset of CRPC transitions from AR 
dependence to an AR indifferent state. These CRPC-neuroendocrine cancers have been also 
referred to as neuroendocrine prostate cancer and anaplastic cancer [20,21]. This is a highly 
aggressive form of CRPC that may emerge in the setting of prolonged androgen-targeting 
therapy [22]. Improved characterization of this entity at the clinical, histological, and 
molecular level is ongoing [20]. Currently there are no standard approaches to treating 
CRPC-neuroendocrine cancers, which are associated with a mean 7-mo survival time. 
Several groups have now reported altered signaling pathways that may represent therapeutic 
target options. These include engagement of N-myc signaling and upregulation of aurora 
kinase A [23]—importantly, aurora kinase A is a druggable target, with clinical trials 
ongoing. Such studies may define the paradigm of bedside to bench to bedside medicine that 
can represent the hallmark of biomarker-driven therapy.
3.1.3 RCC—the VHL/hypoxia inducible factor pathway—RCCs represent a diverse 
collection of histological subtypes, each with specific subsets of underlying molecular 
alterations. Clear cell RCC (ccRCC), the most common and among the most aggressive 
histological variant, is highly associated with inactivation of the tumor suppressor VHL [24]. 
The VHL gene undergoes inactivation via point mutations, genomic deletions, and gene 
methylation in ccRCC. The VHL protein normally promotes ubiquitination and degradation 
of hypoxia inducible factors (HIFs) such as HIF1α and HIF2α, transcription factors that act 
as key regulators of the hypoxic response. Inactivation of VHL in RCC leads to increased 
HIFα expression, and increased activation of targets genes such as VEGF and PDGF [24].
Because of the universality of VHL inactivation and activation of the HIF/vascular 
endothelial growth factor (VEGF) pathways in RCC, interference with downstream effects 
of HIF (in particular VEGF and PDGF signaling) emerged as a major focus of drug 
development and clinical research over the past decade. Approved agents targeting these 
pathways include bevacizumab (Avastin), a humanized monoclonal antibody that binds 
VEGF, and orally active inhibitors targeting multiple tyrosine kinases and growth factor 
receptors (including VEGFR and PDGFR signaling)—these include sorafenib (Nexavar), 
sunitinib (Sutent), pazopanib (Votrient), and axitinib (Inlyta). The early trials employing 
bevacizumab demonstrated proof of principle in human patients that agents inhibiting VEGF 
signaling could significantly alter tumor progression in RCC [25,26]. Since then, antitumor 
activity of these agents has been well established in a series of phase 3 clinical trials, with 
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improvement in both progression-free and overall survival [27–31]. However, molecular 
predictors of response to these agents remain unclear. Alterations in the VHL-VEGF 
signaling axis do not perfectly correlate with response [32]. These agents also have activity 
in nonclear cell histologies of RCC, which classically do not display genomic alterations in 
these signaling pathways. Clearly, ongoing research has the potential to identify markers that 
may allow substratification of RCC patients to individualized treatment regimens.
3.1.4 RCC—mTOR Signaling—mTOR is an intracellular kinase that acts as a signaling 
node in the phosphoinositide 3-kinase (PI3-kinase)/Akt pathway, and functions to coordinate 
a number of cellular events surrounding growth and energy sensing and regulation, including 
regulation of protein translation, degradation, and signaling. Like VHL inactivation and 
upregulation of hypoxia transcriptional programs, activation of the mTOR/PI3K pathway is 
common in RCC [33]. Genomic alterations in this pathway are relatively uncommon when 
estimated from a single tumor sample, with mutations in genes such as MTOR, TSC1, 
PIK3CA, and PTEN occurring in less than 10% of RCC patients [34]. However, assessment 
of tumor heterogeneity in RCC and definition of tumor evolution using phylogenetic trees 
has helped reshape biological understanding and clinical implications of these findings. It is 
increasingly clear that somatic mutations in the mTOR pathway display clear evidence of 
intratumor heterogeneity, commonly occurring in some tumor subclones but not others. 
Somatic mutations in this pathway therefore occur later in tumor evolution than VHL and 3p 
loss of heterozygosity. Tumor sampling bias inherent to such intratumor heterogeneity 
hinders approaches to define activation of the mTOR pathway in order to guide therapy 
[35,36]. Inhibitors of mTOR signaling are currently used as standard options for poor risk 
RCC patients. Initial trials showed activity of temsirolimus in RCC, improving both PFS and 
OS compared with interferon-α [37,38]. Further analyses suggested activity in both ccRCC 
and other subtypes, and temsirolimus was subsequently approved for therapy of advanced 
RCC. The oral agent everolimus was shown to improve survival compared with placebo in 
patients with progressive disease after tyrosine kinase inhibitor therapy [39], and is currently 
being evaluated as an adjuvant therapy for patients at increased risk for progression 
following radical nephrectomy (NCT 01120249). These mTOR-directed therapies continue 
to be a mainstay of the armentarium in advanced RCC. In addition, mTOR inhibition has 
emerged as a standard therapy in renal angiomyolipoma [40,41], consistent with the critical 
role of the tuberous sclerosis complex-mTOR pathway in the pathogenesis of these lesions 
[42].
3.1.5 Targeted therapy—conclusions—In general, the targeted agents described above
—in both prostate cancer and RCC examples—improve patient survival compared with prior 
generations of therapy, while at the same time displaying milder toxicity profiles. However, 
they do not represent curative therapies—complete responses are highly uncommon, and the 
survival advantages displayed are measured in months, not years. Additional studies and 
clinical trials are still needed to improve current practice and better understand predictors of 
response, sequencing of agents, and comparative efficacy of the current agents.
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3.2 Predictors of response to standard of care therapies
The definition of biomarkers that can predict the success or failure of standard of care 
therapies is one of the most important areas of active research in urologic oncology. This has 
the potential for major impact on patients’ lives by enriching treated patients for those likely 
to respond, improving the overall response rates for therapies with limited response rates 
overall (but dramatic response in a subset of patients), and allowing patients with a low 
likelihood of response to move on to other lines of treatment or to clinical trials.
3.2.1 Predictors of response to platinum chemotherapy in urothelial cancer—
Perhaps the most impressive recent example of this paradigm in urology is predictors of 
response to platinum chemotherapy in urothelial cancer. Level I evidence supports the utility 
of platinum-based chemotherapy regimens in the metastatic [43] and neoadjuvant settings 
[44,45]. In the neoadjuvant setting, methotrexate, vinblastine, Adriamycin, and cisplatin and 
other regimens have shown improved overall survival compared with radical cystectomy 
alone [44,45]. However, the absolute increase in overall survival is small (about 5% at 5 yr) 
based on meta-analyses [46–48], leading many to question the general application of the 
neoadjuvant approach to all patients with muscle invasive bladder cancer [49]. Importantly, 
patients who show complete response of the primary tumor (pT0N0 at cystectomy) appear to 
have the most major benefit in terms of overall survival.
It is clear that not all patients benefit from cisplatin-containing chemotherapy regimens, and 
morbidity is not trivial, but a minority of patients has a striking (and possibly curative) 
response. Therefore, defining the subset of patients and tumors likely to respond could have 
major impact [49]. Many studies in the past have examined candidate predictive biomarkers 
for cisplatin response—results have been mixed, and despite decades of research, no 
biomarkers to date have shown adequate predictive value to be currently utilized in the clinic 
[50]. However, the recent advent of next-generation technologies for unbiased, genome-wide 
molecular profiling of cancers has renewed hope for defining these biomarkers. Van Allen 
and colleagues [51] performed whole-exome sequencing on pretreatment muscle-invasive 
urothelial carcinoma from a defined set of patients with either a complete pathologic 
response/residual carcinoma in situ only or persistent muscle invasive cancer following 
cisplatin-based neoadjuvant chemotherapy. They identified somatic mutations in ERCC2, a 
component of the nucleotide excision repair system, as occurring preferentially in 
responders. Similarly, Plimack et al [52] showed that lesions in DNA repair genes ATM, 
RB1, and FANCC predicted pathologic response to neoadjuvant cisplatin. Others have 
reported alterations in genes affecting other DNA repair pathways as potentially important 
for prognosis, reinforcing this theme [53,54].
Other studies have revealed different potential biomarkers of response to platinum-based 
chemotherapy regimens. Utilizing targeted sequencing of urothelial carcinoma (muscle 
invasive and metastatic tumors) from patients treated with platinum-based chemotherapy 
regimens, Groenendijk and colleagues [55] reported that ERBB2 mutations were associated 
with improved response to neoadjuvant chemotherapy. The Southwest Oncology Group has 
initiated an intergroup clinical trial to validate the COXEN algorithm as a predictive marker 
for response to neaodjuvant chemotherapy prior to radical cystectomy (NCT 02177695). If 
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validated, a phase 3 trial will be initiated to evaluate COXEN-directed neoadjuvant 
chemotherapy. Finally, distinct subtypes of bladder cancer have also been identified at the 
molecular level, including basal and luminal subtypes (similar to breast cancer) and a 
chemoresistant subtype with a distinct signature of p53 activation [56]. Heterogeneity at the 
level of tumor itself, stage of disease, patient characteristics, and treatment variability, 
complicate interpretation of these studies across cohorts, and necessitate extensive validation 
in well-annotated and more homogeneous patient cohorts. Further prospective data will be 
necessary to integrate all these findings, and most importantly, define the true clinical utility 
of any markers in practice.
3.2.2 CRPC and DNA repair in prostate cancer—A recent landmark study exposes 
the molecular underpinnings of CRPC and provides unprecedented insight to biology and 
mechanisms of therapy resistance in this disease. The SU2C/PCF Prostate Dream Team 
performed comprehensive molecular characterization of the metastatic tumors in 150 men 
with CRPC, revealing a high degree of actionable events, including frequent alterations in 
AR and PI3K signaling [10]. Furthermore, nearly 20% of CRPC samples harbored somatic 
genomic lesions in components of DNA repair pathways (such as BRCA2, BRCA1, and 
ATM). This is especially timely given the recent emergence of polyadenosine diphosphate 
ribose polymerase inhibitors as therapeutic options for patients with DNA repair deficient 
cancers. A phase 2 trial of the polyadenosine diphosphate ribose polymerase inihibitor 
olaparib in metastatic CRPC showed patient responses specifically associated with defects in 
DNA repair pathways [57], with further trials ongoing. Platinum agents are reported to have 
similar activity in this patient population [58]. Furthermore, emerging data also suggest that 
CRPC patients have a surprising prevalence of germline defects in DNA repair genes (eg, 
BRCA carriers), expanding the potential impact [59].
3.3 Immunotherapy
Urologic malignancies have a relatively long history of successful treatment with agents 
modulating the immune response to tumors. These include the standard of care use of 
bacillus Calmette-Guérin in urothelial cancer, and application of agents such as IL-2 and 
interferon in the armamentarium against RCC [60,61]. Interestingly, like many therapies, 
there appears to be specific subsets of patients with robust and often durable responses to 
these agents [62–64]. Newer approaches that have focused on the inhibition of immune 
checkpoint molecules that can restrict antitumor immune responses have also shown 
promise. Therapy targeting the cytotoxic T-lymphocyte-associated protein 4 T-cell 
checkpoint receptor (eg, ipilumimab) has shown some suggestion of response in prostate 
cancer clinical trials. In RCC, limited human trials have shown potentially impressive 
response rates using agents targeting the programmed cell death protein-1/programmed 
death-ligand 1 (PD-L1) interaction [65]. Both anticytotoxic T-lymphocyte-associated protein 
4 and programmed cell death protein-1/PD-L1 therapy are under active investigation in 
urothelial carcinoma, with promising results [66]—perhaps most exciting, responses in 
patients are often early, durable, and associated with expression of targeted relevant 
biomarkers (eg, PD-L1). These studies focusing on immunotherapy in urologic malignancy 
have been extensively reviewed elsewhere; the potential to define predictive biomarkers for 
these classes of agents remains an active area of investigation [67,68]. These approaches 
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target the adaptive immune response and there are also other efforts targeting the innate 
immune response that may help develop better responses in nonresponders in combination 
with adaptive approaches.
3.4 Lessons from outlier responders
Exceptional responders—those patients whose cancers have an unusually robust and positive 
response to specific agents—can inform the biology of these diseases, highlight pathways 
for intervention, and define biomarkers for prediction of a therapeutic response. This 
approach has yielded results. In urothelial carcinoma, genome sequencing revealed that a 
patient with an exceptional response to everolimus harbored mutations in the mTOR and NF 
genes. These alterations were subsequently shown to impact the response of cancer cells to 
everolimus, nominating these alterations as potential biomarkers of response to mTOR 
inhibition [69]. Similarly, a patient with metastatic prostate cancer with exceptional response 
to cisplatin (after suggestion of small cell morphology) was shown to have inactivation of 
the FANCA gene, a key component of DNA repair pathways modulating response to 
platinum-based chemotherapeutics [70]. These reports, while anecdotal in nature, 
underscore the potential utility in gaining mechanistic insight and defining predictive 
markers from outlier responders. Such reports also highlight another challenge—given that 
rare subsets of patients may respond exceptionally well to therapies that may be ineffective 
in a population as a whole, how do we establish the definition of a negative clinical trial? In 
the absence of pre-existing genomic information, the tails of negative trials, consisting of the 
most robust responders in the population, may harbor informative information regarding 
predictive biomarkers.
This idea has real importance as the field of precision medicine evolves in urologic 
oncology. Many distinct, legitimately targetable alterations, with currently available 
therapeutics of proven efficacy, exist in urologic malignancies. However, they may be 
exceptionally rare, and occur in only a few percent of patients, and across different types of 
malignancies rather than enriched in one type. Furthermore, consideration should be given to 
the clonal structure of the tumor and when the targetable somatic alteration occurs during the 
course of tumor evolution [71]. Targetable somatic alterations occurring early on in tumor 
evolution, within the trunk of the tumor's evolutionary tree, present in every cancer cell, may 
provide more robust biomarkers of tumor response than alterations such as the mTOR 
pathway in ccRCC; however, these are subject to tumor sampling bias, usually occurring 
within a cancer subclone, present in some tumor regions but not others [72]. It should also 
be borne in mind that large-scale alterations in whole or parts of chromosomes that are 
currently refractory to contemporary targeted therapy strategies, can also drive tumor 
progression. For instance, in papillary renal cancer driver gene mutations are often subclonal 
alterations, in contrast to large-scale chromosomal alterations that were found to be clonal in 
nature [73].
Now that comprehensive molecular profiling is available on multiple urologic malignancies, 
through The Cancer Genome Atlas, International Cancer Genome Consortium, and other 
efforts, clear examples of rare but clinically important alterations are emerging. 
Amplifications, activating mutations, and gene fusions in the kinase BRAF (a common 
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driver in melanoma and other cancers) occur in roughly 1–5% of prostate cancers—these 
may be targetable with currently available inhibitors [10,74–76]. Amplifications and 
mutations in ERRB2, encoding the growth factor receptor tyrosine kinase HER2/neu, are 
present in about 10% of muscle invasive bladder cancers [77–79]—these cancers may be 
susceptible to trastuzumab (Herceptin). Mutations in the epigenetic modifying enzyme 
IDH1, one of the most common mutations in gliomas, occur in about 1% of prostate cancers 
[10,75]. IDH1 mutation also represents an attractive target for therapy, with promising 
preclinical data [80]. These are just a few examples of alterations that have high promise as 
therapeutic targets, but are identified in only a small minority of patients. Highlighting the 
potential of this approach, the National Cancer Institute has embarked on the Exceptional 
Responders Initiative, a bedside to bench genomic approach to define the molecular 
underpinnings of rare but exceptional patient responses.
This raises an obvious concern: how can we possibly study a biomarker or target that occurs 
in only 1% of a given population? Understanding how to rigorously evaluate comparative 
treatment efficacy and patient responses in this new paradigm will be a critical challenge, 
given the limited number of patients with any one disease that may have the alterations of 
interest. One approach to this that has been suggested and now implemented is the idea of 
the basket trial—a novel form of clinical trial design that has emerged to meet the needs of 
the genomics era. The hypothesis underlying basket trials is that the molecular marker will 
predict tumor response to specific therapies across disease types. Such trials have generated 
considerable interest because they incorporate current information about genomics and 
precision medicine while promising the ability to identify favorable responses to targeted 
therapy with a relatively small number of patients. The National Cancer Institute Molecular 
Analysis for Therapy Choice trial is one prominent example of this approach. However, 
these come with their own unique limitations, including the need for prospectively collected, 
detailed (and expensive) molecular profiling data. In addition, the potential success of each 
basket trial is likely inextricably linked to the reliability of the target or marker in question 
and the specific therapy utilized. Unfortunately, not all therapies will hit the target in all 
cancer types, and not all cancers may respond the same way to effective blockade of all 
pathways. These complicating factors will likely continue force the evolution of clinical trial 
design.
4. Conclusions
Major advances have been made in cataloguing the genomic, transcriptomic, proteomic, and 
epigenetic alterations across urologic malignances. We have an improved understanding of 
the molecular mechanisms underlying these diseases, and therapies aiming to leverage this 
knowledge continue to emerge. Critical steps going forward will be to refine the list of truly 
predictive biomarkers and therapeutic targets, and evaluate their impact in real-world clinical 
settings. The continuing evolution of clinical trial design must proceed with this process, as 
evaluation of novel agents, with novel predictors will require novel approaches to define the 
population to be treated, and define efficacy in that population.
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Fig. 1. 
Landscape of precision urologic oncology. Relevant biological pathways, therapeutic targets, 
and therapies are highlighted for prostate cancer (left), urothelial cancer (center), and renal 
cell carcinoma (right). Therapeutics are outlined in red; biological pathways and targets are 
shown in yellow. Immunotherapy approaches using checkpoint inhibitors (top) may be 
applicable across disease histologies, with the most current evidence in renal and urothelial 
cancer. AR = androgen receptor; CTLA-4 = cytotoxic T-lymphocyte-associated protein 4; 
mTOR = mechanistic target of rapamycin; PD-1 = programmed cell death protein 1; PDGF 
= platelet-derived growth factor; PD-L1 = programmed death-ligand 1; TKIs = tyrosine 
kinase inhibitors; VEGF = vascular endothelial growth factor.
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Table 1
Summary of potential biomarker directed therapy across urologic oncology
Prostate cancer
Therapy Mechanism of action Potential biomarkers References
AR-directed agents
    Enzalutamide
    Abiraterone
    Apalutamide
Inhibition of androgen receptor 
signaling
Androgen receptor mutations/amplifications
AR-V7
Azad et al 2015 [14]
Azad et al 2015 [15]
Salvi et al 2015 [16]
Li et al 2013 [17]
DNA damaging agents
    PARP inhibitors 
(olaparib)
    Platinum 
chemotherapy (cisplatin, 
carboplatin)
Induction of double strand
DNA breaks
Defects in DNA repair genes—BRCA1/2, ATM Robinson et al 2015 [10]
Mateo et al 2015 [57]
Cheng et al 2016 [58]
AURKA inhibitors Aurora kinase inhibition NEPC; AURKA upregulation; increased N-myc 
signaling
Beltran et al 2011 [23]
CTLA-4 inhibitor
    Ipilumimab
Antibody blocking the T-cell 
checkpoint receptor CTLA-4, 
resulting in improved immune 
surveillance
Kwon et al 2014 [81]
Urothelial carcinoma
Therapy Mechanism of action Potential biomarkers References
Platinum chemotherapy
    Cisplatin containing 
regimens: MVAC, GC
Induction of double strand
DNA breaks (and other damage)
DNA repair defects: ERCC2 
mutations
ATM, RB, FANCC alterations
ERBB2 mutations
Van Allen et al 2014 [51]
Groenendijk et al 2015 [55]
Plimack et al 2015 [52]
PD-1/PD-L1 inhibitors
    Nivolumab
    Pembrolizumab
    Atezolizumab
Targeting PD-1/PD-L1 interaction 
resulting in improved immune 
surveillance
PD-L1
High mutational load
Powles et al 2014 [66]
Rosenberg et al 2016 [82]
Renal cell carcinoma
Therapy Mechanism of action Potential biomarkers References
Anti-VEGF
    Bevacizumab
Monoclonal antibody against VEGF VEGF and VEGF related proteins Escudier et al 2008 [83]
Rini et al 2008 [84]
Tyrosine kinase inhibitors
    Sunitinib
    Sorafanib
    Pazopanib
    Axitinib
Inhibition of receptor tyrosine kinases 
downstream of VHL/HIF-1: VEGFR, PDGFR, 
etc.
VEGF and VEGF related proteins Rini et al 2008 [84]
Escudier et al 2009 [85]
mTOR inhibitors
    Temsirolimus
    Everolimus
Inhibition of mTOR mTOR activity (P-S6) Cho et al 2007 [86]
PD-1/PD-L1 inhibitors
    Nivolumab
    Pembrolizumab
    Atezolizumab
Targeting PD-1/PD-L1 interaction resulting in 
improved immune surveillance
PD-L1
High mutational load
Motzer et al 2015 [87]
Taube et al 2014 [88]
AR = androgen receptor; AURKA = aurora kinase A; CTLA-4 = cytotoxic T-lymphocyte-associated protein 4; GC = gemcitabine and cisplatin; 
mTOR = mechanistic target of rapamycin; MVAC = methotrexate, vinblastine, doxorubicin, cisplatin; NEPC = neuroendocrine prostate cancer; 
PARP = polyadenosine diphosphate ribose polymerase; PD-1 = programmed cell death protein 1; PD-L1 = programmed death-ligand 1; VEGF = 
vascular endothelial growth factor.
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